Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tarsons Products Limited (TARSONS.NS)
Kolkata, IN
Established in 1983 and headquartered in Kolkata, India, Tarsons Products Limited specializes in the global manufacturing and distribution of plastic laboratory supplies and scientific instruments. The company's diverse product portfolio features disposable plastic labware, centrifuge and cryogenic equipment, liquid handling systems, and safety products. Its comprehensive catalog further encompasses items such as bottles, carboys, measuring cylinders, cell culture products, electrophoresis apparatus, microscopy and microbiology tools, vacuum desiccators, mini coolers, cryo boxes, beakers, test tube racks, pipette tips, petri dishes, centrifuge tubes, cryogenic and storage vials, Pasteur pipettes, and vortex mixers, among many others. These offerings are vital for research and applications across various scientific disciplines including molecular biology, cell culture, genomics, proteomics, and immunology.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.48% | -4.69% | -5.65% | +8.75% | -7.96% | -11.06% | -46.30% | -62.86% | -74.65% | -74.65% | -74.65% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+7.7% Q1'26: +7.3% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-52.0% Q1'26: -58.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-4.5% Q1'26: -22.1% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+5.1% Q1'26: +4.3% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+1.4% Q1'26: +1.5% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.2% Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×3.33× Q1'26: 2.87× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
3.01B
est: 2.99B (+0.4%)
|
2.83B
est: 2.83B (+0.0%)
|
2.96B
est: 3.19B (-7.0%)
|
3.92B
est: 3.99B (-1.6%)
|
4.32B
4.32B – 4.32B
+8.3% YoY
|
4.88B
4.88B – 4.88B
+13.0% YoY
|
5.81B
5.81B – 5.81B
+19.1% YoY
|
6.91B
6.91B – 6.91B
+18.8% YoY
|
| EBITDA |
1.61B
est: 1.32B (+21.7%)
|
1.42B
est: 1.25B (+13.1%)
|
1.11B
est: 1.28B (-13.2%)
|
1.27B
est: 1.61B (-21.1%)
|
1.74B
1.74B – 1.74B
+8.3% YoY
|
1.96B
1.96B – 1.96B
+13.0% YoY
|
2.34B
2.34B – 2.34B
+19.1% YoY
|
2.78B
2.78B – 2.78B
+18.8% YoY
|
| EBIT |
1.39B
est: 1.01B (+37.9%)
|
1.13B
est: 953.11M (+18.7%)
|
707.85M
est: 838.55M (-15.6%)
|
641.87M
est: 1.05B (-38.8%)
|
1.14B
1.14B – 1.14B
+8.3% YoY
|
1.28B
1.28B – 1.28B
+13.0% YoY
|
1.53B
1.53B – 1.53B
+19.1% YoY
|
1.82B
1.82B – 1.82B
+18.8% YoY
|
| Net Income |
1.01B
est: 1.08B (-6.8%)
|
807.14M
est: 807.44M (0.0%)
|
426.40M
est: 370.25M (+15.2%)
|
297.70M
est: 383.34M (-22.3%)
|
346.07M
346.07M – 346.07M
-9.7% YoY
|
622.93M
622.93M – 622.93M
+80.0% YoY
|
1.00B
1.00B – 1.00B
+60.7% YoY
|
1.45B
1.45B – 1.45B
+45.2% YoY
|
| SGA |
104.99M
est: 302.87M (-65.3%)
|
137.53M
est: 286.42M (-52.0%)
|
488.75M
est: 435.34M (+12.3%)
|
868.65M
est: 544.61M (+59.5%)
|
589.83M
589.83M – 589.83M
+8.3% YoY
|
666.48M
666.48M – 666.48M
+13.0% YoY
|
794.10M
794.10M – 794.10M
+19.1% YoY
|
943.43M
943.43M – 943.43M
+18.8% YoY
|
| EPS |
19.46
est: 20.33 (-4.3%)
|
15.17
est: 15.20 (-0.2%)
|
8.01
est: 6.95 (+15.2%)
|
5.60
est: 7.20 (-22.2%)
|
6.50
6.50 – 6.50
-9.7% YoY
|
11.70
11.70 – 11.70
+80.0% YoY
|
18.80
18.80 – 18.80
+60.7% YoY
|
27.30
27.30 – 27.30
+45.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sanjive Sehgal | Chairman, Chief Executive Officer & MD | 43M | male |
| Aryan Sehgal | Whole-time Director | 38M | male |
| Santosh Kumar Agarwal | Chief Financial Officer, Company Secretary & Compliance Officer | 9M | male |
| Lakshmananarayanan Balakrishna Reddy | Vice President of Operations | — | male |
| Mani Kalyan Dusi | Head of Revenue for India & APAC | — | male |
| Subhra Sankar Bose | Head of Human Resource | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TARSONS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
